Provided by Tiger Trade Technology Pte. Ltd.

Kyverna Therapeutics

6.67
-0.1350-1.99%
Volume:260.68K
Turnover:1.75M
Market Cap:412.19M
PE:-2.31
High:6.91
Open:6.80
Low:6.61
Close:6.80
52wk High:13.67
52wk Low:5.30
Shares:61.84M
Float Shares:39.72M
Volume Ratio:0.52
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8809
EPS(LYR):-3.6445
ROE:-87.24%
ROA:-44.51%
PB:2.49
PE(LYR):-1.83

Loading ...

Kyverna Therapeutics, Inc. Expected to Post a Loss of 68 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Kyverna Therapeutics, Inc. (KYTX)

TIPRANKS
·
Jul 28

Kyverna Therapeutics Shares Rise on Manufacturing Deal for Autoimmune Disease Treatment

Dow Jones
·
Jul 27

Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement

TIPRANKS
·
Jul 27

Kyverna Signs Commercial Manufacturing, Supply Deal with ElevateBio for Miv-cel CAR-T Therapy

Reuters
·
Jul 27

Kyverna Therapeutics - Agreement Provides Scalable Miv-Cel Supply for Potential SPS and Gmg Launches

THOMSON REUTERS
·
Jul 27

Kyverna Therapeutics and Elevatebio Enter into Commercial Manufacturing and Supply Agreement for Miv-Cel

THOMSON REUTERS
·
Jul 27

Kyverna Therapeutics - on Track to Complete Rolling Bla Submission for Miv-Cel in SPS in Q4 2026

THOMSON REUTERS
·
Jul 27

Biotech Experts Want FDA Drug Reviews Based on Science, not Politics

Reuters
·
Jul 22

Cue Biopharma Names Dominic Borie Chief Medical Officer, Head of R&D

Reuters
·
Jul 13

Kyverna Therapeutics - Extends $15 Mln Term a Loan Availability Through Dec 31, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 09

Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer

TIPRANKS
·
Jun 22

Kyverna appoints Ritesh Srivastava as chief legal and compliance officer

Reuters
·
Jun 22

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

THOMSON REUTERS
·
Jun 22

Health Rounds: CAR-T therapy brings hope to kidney patients with few transplant options

Reuters
·
Jun 05

Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval

TIPRANKS
·
Jun 04

Kyverna Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 04

Kyverna Therapeutics presents updated COMPARE trial data at EULAR

TIPRANKS
·
Jun 03

Kyverna says miv-cel CAR-T drives ACR70 response in Phase 1 trial in refractory ACPA-positive rheumatoid arthritis

Reuters
·
Jun 03

Kyverna Therapeutics Highlights Updated Miv-Cel Data at Eular Demonstrating Substantial Reduction in Disease Activity in Acpa-Positive, Treatment Refractory Rheumatoid Arthritis

THOMSON REUTERS
·
Jun 03